Michael Toporek - 30 Mar 2026 Form 4/A - Amendment Insider Report for Capstone Holding Corp. (CAPS)

Reporting relationship: Director
Issuer ticker: CAPS
Reported as of: 30 Mar 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 24 Jul 2026, 16:28:28 UTC
Original report date: 01 Apr 2026
Prior SEC filing: 03 Dec 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Toporek

Key filing fact

Michael Toporek filed Form 4/A - Amendment for Capstone Holding Corp. (CAPS) on 24 Jul 2026.

Key facts

This page summarizes Michael Toporek's Form 4/A - Amendment filing for Capstone Holding Corp. (CAPS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jul 2026, 16:28.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001243628 Primary reporting owner

TOPOREK MICHAEL

Relationship: Director
Address: 18400 76TH AVENUE, TINLEY PARK
Signature: /s/ Michael Toporek
Signature date: 24 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAPS transaction

Common Stock

Award

Transaction value
Shares: +356,250
Change %: +1006%
Price
Shares after: 391,678
Date: 30 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This Form 4/A is being filed solely to correct the nature of the shares and the vesting schedule reported as granted on April 1, 2026. This amendment reflects that the shares granted were shares of common stock, rather than restricted stock units, and corrects the vesting schedule of the shares granted.

Footnote F2

Including 356,250 shares of common stock granted to the Reporting Person on March 30, 2026 as restricted stock awards, for no consideration. The restricted stock awards will vest in full only upon the Reporting Person's death or disability, removal from the Board of Directors other than for Cause, or failure to be re-elected to the Board of Directors. If the Reporting Person voluntarily resigns from the Board of Directors before the applicable vesting event, the restricted stock awards will be forfeited.

Footnote F3

Excludes 121,774 shares controlled by the Reporting Person, through his control of BP Peptides, LLC.